ChulaCov19 BNA159 vaccine
/ Chulalongkorn University, BioNet Asia
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 14, 2025
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
(clinicaltrials.gov)
- P2 | N=150 | Completed | Sponsor: Technovalia, Pty Ltd | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 10, 2024
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
(clinicaltrials.gov)
- P2 | N=150 | Active, not recruiting | Sponsor: Technovalia, Pty Ltd | Recruiting ➔ Active, not recruiting | Trial completion date: Feb 2024 ➔ Sep 2024 | Trial primary completion date: Sep 2023 ➔ Jul 2024
Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
April 19, 2023
Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults
(clinicaltrials.gov)
- P2 | N=150 | Recruiting | Sponsor: Technovalia, Pty Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Feb 2024 | Trial primary completion date: Apr 2023 ➔ Sep 2023
Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL2 • IL4
November 04, 2022
Immunogenicity and Safety of ChulaCov19 BNA159 Vaccine as a Booster Dose in Adults
(clinicaltrials.gov)
- P2 | N=150 | Not yet recruiting | Sponsor: Technovalia, Pty Ltd
New P2 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IL2 • IL4
1 to 4
Of
4
Go to page
1